Dissociation of VE-PTP from VE-cadherin is required for leukocyte extravasation and for VEGF-induced vascular permeability in vivo
Broermann, Andre, Winderlich, Mark, Block, Helena, Frye, Maike, Rossaint, Jan, Zarbock, Alexander, Cagna, Giuseppe, Linnepe, Ruth, Schulte, Dörte, Nottebaum, Astrid Fee, Vestweber, Dietmar
Published in The Journal of experimental medicine (21.11.2011)
Published in The Journal of experimental medicine (21.11.2011)
Get full text
Journal Article
VE-PTP controls blood vessel development by balancing Tie-2 activity
Winderlich, Mark, Keller, Linda, Cagna, Giuseppe, Broermann, Andre, Kamenyeva, Olena, Kiefer, Friedemann, Deutsch, Urban, Nottebaum, Astrid F, Vestweber, Dietmar
Published in The Journal of cell biology (18.05.2009)
Published in The Journal of cell biology (18.05.2009)
Get full text
Journal Article
VE-PTP maintains the endothelial barrier via plakoglobin and becomes dissociated from VE-cadherin by leukocytes and by VEGF
Nottebaum, Astrid F, Cagna, Giuseppe, Winderlich, Mark, Gamp, Alexander C, Linnepe, Ruth, Polaschegg, Christian, Filippova, Kristina, Lyck, Ruth, Engelhardt, Britta, Kamenyeva, Olena, Bixel, Maria Gabriele, Butz, Stefan, Vestweber, Dietmar
Published in The Journal of experimental medicine (24.11.2008)
Published in The Journal of experimental medicine (24.11.2008)
Get full text
Journal Article
Leukocyte extravasation and vascular permeability are each controlled in vivo by different tyrosine residues of VE-cadherin
Wessel, Florian, Winderlich, Mark, Holm, Maren, Frye, Maike, Rivera-Galdos, Ronmy, Vockel, Matthias, Linnepe, Ruth, Ipe, Ute, Stadtmann, Anika, Zarbock, Alexander, Nottebaum, Astrid F, Vestweber, Dietmar
Published in Nature immunology (01.03.2014)
Published in Nature immunology (01.03.2014)
Get full text
Journal Article
Cell adhesion dynamics at endothelial junctions: VE-cadherin as a major player
Vestweber, Dietmar, Winderlich, Mark, Cagna, Giuseppe, Nottebaum, Astrid F
Published in Trends in cell biology (01.01.2009)
Published in Trends in cell biology (01.01.2009)
Get full text
Journal Article
CD19 Treatment paradigm for an anti-CD19 antibody and venetoclax combination treatment
KELEMEN PETER, SCHWARZ MICHAEL, WEINELT DOMINIKA, WINDERLICH MARK, HEEGER STEFFEN
Year of Publication 01.08.2024
Get full text
Year of Publication 01.08.2024
Patent
Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts
Koh, Gou Young, Wirkkala, Riikka, Olsen, Bjorn R, Saharinen, Pipsa, Nottebaum, Astrid, Alitalo, Kari, Anisimov, Andrey, Winderlich, Mark, Vestweber, Dietmar, Deutsch, Urban, Eklund, Lauri, Miettinen, Juho
Published in Nature cell biology (01.05.2008)
Published in Nature cell biology (01.05.2008)
Get full text
Journal Article
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study
Nowakowski, Grzegorz S, Yoon, Dok Hyun, Peters, Anthea, Mondello, Patrizia, Joffe, Erel, Fleury, Isabelle, Greil, Richard, Ku, Matthew, Marks, Reinhard, Kim, Kibum, Zinzani, Pier Luigi, Trotman, Judith, Huang, Dan, Waltl, Eva E, Winderlich, Mark, Kurukulasuriya, Nuwan C, Ambarkhane, Sumeet, Hess, Georg, Salles, Gilles
Published in Clinical cancer research (15.09.2022)
Published in Clinical cancer research (15.09.2022)
Get full text
Journal Article
Estimation of Long-Term Survival with Tafasitamab + Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Salles, Gilles, Goswami, Budhaditya, Bagnardi, Vincenzo, Dey, Debarshi, Winderlich, Mark, Ambarkhane, Sumeet, Huang, Dan, Nowakowski, Grzegorz S.
Published in Blood (05.11.2020)
Published in Blood (05.11.2020)
Get full text
Journal Article
A phase 2a, single‐arm, open‐label study of tafasitamab, a humanized, Fc‐modified, anti‐CD19 antibody, in patients with relapsed/refractory B‐precursor cell acute lymphoblastic leukemia
Klisovic, Rebecca B., Leung, Wing H., Brugger, Wolfram, Dirnberger‐Hertweck, Maren, Winderlich, Mark, Ambarkhane, Sumeet V., Jabbour, Elias J.
Published in Cancer (15.11.2021)
Published in Cancer (15.11.2021)
Get full text
Journal Article
RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Zinzani, Pier Luigi, Rodgers, Thomas, Marino, Dario, Frezzato, Maurizio, Barbui, Anna Maria, Castellino, Claudia, Meli, Erika, Fowler, Nathan H, Salles, Gilles, Feinberg, Bruce, Kurukulasuriya, Nuwan C, Tillmanns, Sascha, Parche, Stephan, Dey, Debarshi, Fingerle-Rowson, Günter, Ambarkhane, Sumeet, Winderlich, Mark, Nowakowski, Grzegorz S
Published in Clinical cancer research (15.11.2021)
Published in Clinical cancer research (15.11.2021)
Get full text
Journal Article
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma
Nowakowski, Grzegorz S., Yoon, Dok Hyun, Mondello, Patrizia, Joffe, Erel, Peters, Anthea, Fleury, Isabelle, Greil, Richard, Ku, Matthew, Marks, Reinhard, Kim, Kibum, Zinzani, Pier Luigi, Trotman, Judith, Sabatelli, Lorenzo, Waltl, Eva E., Winderlich, Mark, Sporchia, Andrea, Kurukulasuriya, Nuwan C., Cordoba, Raul, Hess, Georg, Salles, Gilles
Published in Annals of hematology (01.07.2023)
Published in Annals of hematology (01.07.2023)
Get full text
Journal Article
O17-2 Tafasitamab + lenalidomide versus lenalidomide monotherapy in transplant-ineligible patients with R/R DLBCL (RE-MIND)
Nowakowski, Grzegorz, Rodgers, Thomas, Marino, Dario, Frezzato, Maurizio, Barbui, Anna Maria, Castellino, Claudia, Meli, Erika, Fowler, Nathan H., Feinberg, Bruce, Tillmanns, Sascha, Parche, Stephan, Fingerle-Rowson, Gunter, Winderlich, Mark, Ambarkhane, Sumeet, Salles, Gilles, Zinzani, Pier Luigi
Published in Annals of oncology (01.07.2021)
Published in Annals of oncology (01.07.2021)
Get full text
Journal Article
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial
Raab, Marc S, Engelhardt, Monika, Blank, Antje, Goldschmidt, Hartmut, Agis, Hermine, Blau, Igor W, Einsele, Hermann, Ferstl, Barbara, Schub, Natalie, Röllig, Christoph, Weisel, Katja, Winderlich, Mark, Griese, Janine, Härtle, Stefan, Weirather, Johannes, Jarutat, Tiantom, Peschel, Christian, Chatterjee, Manik
Published in The Lancet. Haematology (01.05.2020)
Published in The Lancet. Haematology (01.05.2020)
Get more information
Journal Article
Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Nowakowski, Grzegorz S., Yoon, Dok Hyun, Mondello, Patrizia, Joffe, Erel, Fleury, Isabelle, Peters, Anthea, Greil, Richard, Ku, Matthew, Marks, Reinhard, Kim, Kibum, Zinzani, Pier Luigi Luigi, Trotman, Judith, Sabatelli, Lorenzo, Huang, Dan, Waltl, Eva E., Winderlich, Mark, Ambarkhane, Sumeet, Kurukulasuriya, Nuwan C., Cordoba, Raul, Hess, Georg, Salles, Gilles
Published in Blood (23.11.2021)
Published in Blood (23.11.2021)
Get full text
Journal Article
제한된 수의 NK 세포를 갖는 환자에서의 항-CD19 치료제
FINGERLE ROWSON GUENTER, ENDELL JAN, KUFFER CHRISTIAN, WINDERLICH MARK
Year of Publication 18.01.2022
Get full text
Year of Publication 18.01.2022
Patent
RE-MIND study: A propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
Nowakowski, Grzegorz S., Rodgers, Thomas David, Marino, Dario, Frezzato, Maurizio, Barbui, Anna Maria, Castellino, Claudia, Meli, Erika, Fowler, Nathan Hale, Feinberg, Bruce A., Tillmanns, Sascha, Parche, Stephan, Fingerle-Rowson, Guenter, Winderlich, Mark, Ambarkhane, Sumeet Vijay, Salles, Gilles A., Zinzani, Pier Luigi
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article
Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma
Nowakowski, Grzegorz S., Yoon, Dok Hyun, Mondello, Patrizia, Joffe, Erel, Peters, Anthea, Fleury, Isabelle, Greil, Richard, Ku, Matthew, Marks, Reinhard, Kim, Kibum, Zinzani, Pier Luigi, Trotman, Judith, Sabatelli, Lorenzo, Waltl, Eva E., Winderlich, Mark, Sporchia, Andrea, Kurukulasuriya, Nuwan C., Cordoba, Raul, Hess, Georg, Salles, Gilles
Published in Annals of hematology (01.09.2023)
Published in Annals of hematology (01.09.2023)
Get full text
Journal Article
MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation Study
Raab, Marc S, Chatterjee, Manik, Goldschmidt, Hartmut, Agis, Hermine, Blau, Igor, Einsele, Hermann, Engelhardt, Monika, Ferstl, Barbara, Gramatzki, Martin, Rollig, Christoph, Weisel, Katja, Jarutat, Tiantom, Weinelt, Dominika, Winderlich, Mark, Peschel, Christian
Published in Blood (29.11.2018)
Published in Blood (29.11.2018)
Get full text
Journal Article